Best-Worst Scaling HTA

Best-Worst Scaling (BWS) survey of barriers and facilitators of the uptake of Health Technology Assessment (HTA) in Austria

Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care internationally. This empirical study aims at collecting data on the relative importance of selected barriers and facilitators of the uptake of HTA studies in Austria by surveying relevant national stakeholders. Best-worst scaling modelling technique will be applied in the analysis.

Comparison of analyses for the Best-Worst Scaling (BWS)

Different methods are used in practice to analyse Best-Worst Scaling (BWS) data in health services research and yet, it is unknown to what extent the different methods yield different conclusions. Hence, to deepen the understanding of conducting and interpreting BWS studies, this study aims to empirically test the comparability of different methods of analysis (i.e. count analysis; multinomial logit, mixed logit and rank-ordered logistic regression models; latent class analysis; Hierarchical Bayes estimation), using data from a BWS that quantifies the importance of barriers and facilitators to the usage of HTA in several European countries.

Dates: 2017

Collaborator(s):
Department of Health Services Research, Maastricht University, NL

Information:
Susanne Mayer, Judit Simon, Chiara Feig, Kei Long Cheung

Publication(s):

• Feig C, Cheung KL, Hiligsmann M, Evers S, Simon J, Mayer S (2018): Best-worst scaling to assess the most important barriers and facilitators for the use of Health Technology Assessment in Austria. Expert Review of Pharmacoeconomics & Outcomes Research. 18(2), 223-232.
• Cheung KL, Mayer S, Simon J, de Vries H, Evers S, Kremer I, Hiligsmann M (2018): Comparison of statistical analysis methods for object case best-worst scaling. Journal of Medical Economics. doi.org/10.1080/13696998.2018.1553781
• Cheung KL, Evers S, de Vries H, Levy P, Pokhrel S, Jones T, Danner M, Wentlandt J, Knufinke L, Mayer S, Hiligsmann M (2018): Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Review of Pharmacoeconomics & Outcomes Research, 8(3), 297-304, DOI:10.1080/14737167.2018.1421459.